PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
|
abstract
|
In cancer patients receiving fluoropyrimidine-based chemo-therapy,
there is extensive inter-individual variability in plasma drug
concentrations and the severity of chemo-therapy-related toxicity. A
strong association has been shown for plasma concentrations and
drug-related toxicity as well as clinical outcome in 5-fluorouracil
treated cancer patients. In spite of the identification of some
genetic risk factors that contribute to this inter-individual
variability, a majority of toxicity occurrences remain unexplained.
Cur-rently, variability in drug exposure related to BSA-based dosing
hampers the identification of genetic factors con-tributing to
individual FP toxicity risk and the quantification of their clinical
relevance. Thus, the power of association studies can be improved by
accounting for differences in individual drug exposure.
|
| |
|
|
type of project
|
clinical studies
|
|
status
|
ongoing - recruiting phase
|
|
start of project
|
2016
|
|
end of project
|
2020
|
|
responsible person
|
PD Dr. med. Markus Jörger
|
additional links & downloads
